Baldwin Wealth Partners LLC MA Lowers Holdings in Novartis AG (NYSE:NVS)

Baldwin Wealth Partners LLC MA lowered its holdings in Novartis AG (NYSE:NVS) by 11.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 48,278 shares of the company’s stock after selling 6,527 shares during the quarter. Baldwin Wealth Partners LLC MA’s holdings in Novartis were worth $4,698,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. World Investment Advisors LLC purchased a new stake in Novartis in the 3rd quarter valued at about $30,063,000. Fisher Asset Management LLC increased its position in shares of Novartis by 15.7% during the third quarter. Fisher Asset Management LLC now owns 1,706,009 shares of the company’s stock valued at $196,225,000 after acquiring an additional 231,851 shares during the last quarter. Mediolanum International Funds Ltd purchased a new stake in shares of Novartis in the 3rd quarter valued at approximately $24,096,000. Public Employees Retirement System of Ohio acquired a new position in shares of Novartis in the 3rd quarter worth approximately $21,078,000. Finally, International Assets Investment Management LLC purchased a new position in shares of Novartis during the 3rd quarter worth approximately $19,878,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Price Performance

NVS stock opened at $102.29 on Monday. Novartis AG has a 1 year low of $92.35 and a 1 year high of $120.92. The firm has a market capitalization of $209.08 billion, a P/E ratio of 11.89, a P/E/G ratio of 1.42 and a beta of 0.57. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. The business’s 50-day moving average is $100.09 and its two-hundred day moving average is $108.69.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $12.82 billion for the quarter, compared to analyst estimates of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same period last year, the business earned $1.74 EPS. Analysts anticipate that Novartis AG will post 7.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on NVS shares. HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Erste Group Bank restated a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Finally, BMO Capital Markets boosted their price target on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. Two research analysts have rated the stock with a sell rating and six have issued a hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $123.38.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.